Avita Medical Limited
(ASX:AVH) has announced it has been awarded a US$7.96M contract by a US Federal authority to support the company bring its ReCell® product to market.
The Biomedical Advanced Research and Development Authority will help Avita fund the completion of its FDA approval trial for ReCell®, a technology that helps clinicians create wound healing treatments using a patient’s own skin cells, at the point of care.
The funding from BARDA to Avita is in line with the federal authority’s mandate to support the government in developing medical countermeasures for possible mass casualty events.
The BARDA funding will also help Avita procure 5000 devices for the treatment program as well as fund an education program for burns surgeons across the US.
Avita Medical Limited reported a net loss of $4.93 million at 31 December 2015.
